click below
click below
Normal Size Small Size show me how
MSK
| Pharmacologic Category | Generic | Brand | Classification | Indication | Key Side effects | US Boxed Warnings | Other Notes |
|---|---|---|---|---|---|---|---|
| Alpha2 agonist | tizanidine (PO) | Zanaflex | n/a | Spasticity | Key Side Effects: drowsiness, hypotension, dizziness, xerostomia, weakness | n/a | n/a |
| Aminoquinolone | hydroxychloroquine (PO) | Plaquenil | n/a | RA, SLE, malaria | Key Side Effects: retinal toxicity, rash, diarrhea | n/a | Other Notes: long-term use has been associated with cardiomyopathy, bone marrow suppression, QT prolongation, and neuromuscular effects (i.e., myopathy, palsies, and progressive weakness) |
| NSAID | diclofenac (topical) | Voltaren Gel | OTC | OA | Key Side Effects: pruritus, rash | n/a | n/a |
| NSAID | diclofenac (PO) | Voltaren | n/a | OA, RA, acute pain | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID | ibuprofen (PO) | Motrin, Advil | OTC | OA, RA, acute pain | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID | meloxicam (PO) | Mobic | n/a | OA, RA, acute pain | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID | indomethacin (PO) | Indocin | n/a | OA, RA, acute pain, gout | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID | naproxen (PO) | Naprosyn, Anaprox, Aleve | OTC | OA, RA, acute pain, gout | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID | ketorolac (PO, IV) | Toradol | n/a | Pain | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase risk of serious (may be fatal) cardiovascular thrombotic events, MI, & stroke; may increase risk for serious (may be fatal) gastrointestinal side events including ulceration, bleeding, & perforation (ketorolac): for short term use (≤ 5 ) | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| NSAID, COX-2 selective | celecoxib (PO) | Celebrex | n/a | OA, RA, acute pain | Key Side Effects: diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | Other Notes: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
| Skeletal muscle relaxant | cyclobenzaprine (PO) | Flexeril, Amrix, Fexmid | n/a | Muscle spasm | Key Side Effects: drowsiness, dizziness, xerostomia, fatigue | n/a | Other Notes: use may cause prolonged cardiac arrhythmias, and tachycardia; CI within 14 days of MAOI therapy |
| Skeletal muscle relaxant | baclofen (PO) | n/a | n/a | Spasticity | Key Side Effects: drowsiness | n/a | n/a |
| Skeletal muscle relaxant | methocarbamol (PO) | Robaxin | n/a | Muscle spasm | Key Side Effects: drowsiness | n/a | n/a |
| Transdermal: topical analgesic IV: antiarrhythmic | lidocaine (transdermal, IV) | Transdermal: Lidoderm, IV: Xylocaine | Transdermal: OTC | Transdermal: pain, IV: ventricular arrhythmias | Key Side Effects (transdermal): dermatitis, erythema, urticaria, skin depigmentation, skin edema. Key Side Effects (IV): bradycardia | n/a | Other Notes: patch may remain in place for up to 12 hours in any 24-hour period, patch may be cut |
| Antigout agent | colchicine (PO) | Colcrys | n/a | Gout | Key Side Effects: diarrhea, nausea, vomiting, bone marrow suppression, myopathy (including rhabdomyolysis) | n/a | n/a |
| Xanthine oxidase Inhibitor | allopurinol (PO) | Zyloprim | n/a | Gout | Key Side Effects: diarrhea, nausea, rash, leukopenia, thrombocytopenia | n/a | Other Notes: rare association with severe (and potentially fatal) allopurinol hypersensitivity syndrome (risk highest in certain Asian populations) |
| Depolarizing neuromuscular blocking agent | succinylcholine (IV) | Anectine | n/a | Neuromuscular blockade for intubation or procedures | Key Side Effects: hyperkalemia, myalgia, malignant hyperthermia (rare) | US Boxed Warning: acute rhabdomyolysis and hyperkalemia leading to cardiac arrest and death in pediatric patients with undiagnosed skeletal muscle disease | n/a |
| Anti-tumor necrosis factor alpha inhibitor | etanercept (SQ) | Enbrel | n/a | RA | Key Side Effects: infection, injection site reaction, headache, nausea | US Boxed Warning: serious infections, malignancies such as lymphoma | n/a |
| Anti-tumor necrosis factor alpha inhibitor | adalimumab (SQ) | Humira | n/a | RA, Crohn’s Disease, Ulcerative Colitis | Key Side Effects: infection, injection site reaction, headache, nausea | US Boxed Warning: serious infections, malignancies such as lymphoma | n/a |